Search research articles
Contact Us
Filters
Showing results (51-60 of 78) with videos related to
Page
of 8
Sort By:
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|
July 2, 2005
Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy
M J Dinubile, I Friedland, C Y Chan, et al.
Jac-Antimicrobial Resistance
|
January 15, 2024
Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21
James A Karlowsky, Sibylle H Lob, Karri A Bauer, et al.
International Journal of Antimicrobial Agents
|
June 24, 2023
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020
James A Karlowsky, Sibylle H Lob, Wei-Ting Chen, et al.
Journal of Global Antimicrobial Resistance
|
December 13, 2021
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019
Sibylle H Lob, Krystyna M Kazmierczak, Wei-Ting Chen, et al.
The Journal of Antimicrobial Chemotherapy
|
April 17, 2018
In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme
James A Karlowsky, Sibylle H Lob, Krystyna M Kazmierczak, et al.
The Journal of Antimicrobial Chemotherapy
|
May 16, 2019
Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17
Sibylle H Lob, James A Karlowsky, Katherine Young, et al.
Jac-Antimicrobial Resistance
|
June 30, 2023
Susceptibility profile and β-lactamase content of global <i>Pseudomonas aeruginosa</i> isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam-SMART 2016-21
James A Karlowsky, Sibylle H Lob, Mark A Estabrook, et al.
Diagnostic Microbiology and Infectious Disease
|
March 15, 2017
Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program
Sibylle H Lob, Meredith A Hackel, Krystyna M Kazmierczak, et al.
The Journal of Antimicrobial Chemotherapy
|
May 19, 2017
Genomic epidemiology of global VIM-producing Enterobacteriaceae
Yasufumi Matsumura, Gisele Peirano, Rebekah Devinney, et al.
Jac-Antimicrobial Resistance
|
January 25, 2023
<i>In vitro</i> activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and <i>Pseudomonas aeruginosa</i> collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20
James A Karlowsky, Sibylle H Lob, Brune Akrich, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 78) with videos related to
Sort By:
Page
of 8
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|
July 2, 2005
Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy
M J Dinubile, I Friedland, C Y Chan, et al.
Jac-Antimicrobial Resistance
|
January 15, 2024
Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21
James A Karlowsky, Sibylle H Lob, Karri A Bauer, et al.
International Journal of Antimicrobial Agents
|
June 24, 2023
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020
James A Karlowsky, Sibylle H Lob, Wei-Ting Chen, et al.
Journal of Global Antimicrobial Resistance
|
December 13, 2021
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019
Sibylle H Lob, Krystyna M Kazmierczak, Wei-Ting Chen, et al.
The Journal of Antimicrobial Chemotherapy
|
April 17, 2018
In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme
James A Karlowsky, Sibylle H Lob, Krystyna M Kazmierczak, et al.
The Journal of Antimicrobial Chemotherapy
|
May 16, 2019
Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17
Sibylle H Lob, James A Karlowsky, Katherine Young, et al.
Jac-Antimicrobial Resistance
|
June 30, 2023
Susceptibility profile and β-lactamase content of global <i>Pseudomonas aeruginosa</i> isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam-SMART 2016-21
James A Karlowsky, Sibylle H Lob, Mark A Estabrook, et al.
Diagnostic Microbiology and Infectious Disease
|
March 15, 2017
Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program
Sibylle H Lob, Meredith A Hackel, Krystyna M Kazmierczak, et al.
The Journal of Antimicrobial Chemotherapy
|
May 19, 2017
Genomic epidemiology of global VIM-producing Enterobacteriaceae
Yasufumi Matsumura, Gisele Peirano, Rebekah Devinney, et al.
Jac-Antimicrobial Resistance
|
January 25, 2023
<i>In vitro</i> activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and <i>Pseudomonas aeruginosa</i> collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20
James A Karlowsky, Sibylle H Lob, Brune Akrich, et al.
Page
of 8